I love it when our plans come together!
First, Atomera Inc. (ATOM) and now Immunome, Inc. (IMNM).
You’ll recall, I first told you to buy Immunome on January 11, when the stock was trading for less than $13 per share.
Then, on January 27, I pounded the table again. Why? Because the company published its first pre-clinical data demonstrating the potential for its memory b-cell platform in generating a more natural and complete immune response to fight Covid-19.
Even better, the first set of data suggested Immunome’s approach would likely adapt to mutations more effectively.
It all came together at the perfect time, too.
Remember, a few weeks ago the world was first coming to grips with the reality that the first batch of Covid-19 vaccines were not as effective against variants of the virus. Particularly, the South African variant.
And today, we got even more proof why Immunome’s novel approach – and stock – promises to be so valuable.